Company news

Serina Therapeutics, Inc. news in 2026

Serina Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

September 9, 2026

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

April 7, 2026

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

April 2, 2026

Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

March 25, 2026

Serina Therapeutics to Present at the 38th Annual Roth Conference

March 24, 2026

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease

March 18, 2026

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

February 24, 2026

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

February 19, 2026

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease

January 28, 2026

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

January 15, 2026

Decks in 2026